This key study explores the influence of CYP2C9 genetic polymorphisms on the pharmacokinetics (PK) of delta-9-tetrahydrocannabinol (THC) and its active metabolites in Alzheimer’s disease (AD) patients.
Titled ‘A study on CYP2C9 polymorphism, in Puerto Rican Alzheimer's patients and its role in the Pharmacokinetics of ∆-9-tetrahydrocannabinol,’ it is accessible at the European Society of Medicine website.
The research highlights the critical role of CYP2C9 polymorphisms in THC metabolism, highlighting significant variations in the half-life of THC and OH-THC among different CYP2C9 phenotypes. These findings suggest the necessity for personalized dosing strategies to enhance treatment efficacy and safety for Alzheimer’s patients.
Understanding CYP2C9 polymorphisms in Alzheimer’s treatments
Ram Mukunda, CEO of IGC Pharma, said: “We are thrilled to share this significant publication in the European Society of Medicine journal. This research exemplifies our dedication to advancing Alzheimer’s treatment through innovative science. Understanding genetic influences on drug metabolism is vital for developing safe and effective therapies.”
Conducted with a Puerto Rican cohort, the study aligns with IGC Pharma’s commitment to inclusive clinical research. Puerto Rico was strategically selected due to its higher Alzheimer’s prevalence of 12% compared to the continental US rate of 10.7%, ensuring comprehensive data collection and improved therapy accessibility.
IGC Pharma’s leading candidate, IGC-AD1, was tested in a phase 1 multiple ascending dose (MAD) trial. The study’s outcomes support the potential for personalized medicine approaches in treating Alzheimer's.
Personalized medicine: Tailoring THC doses for Alzheimer’s patients
Dr Jagadeesh Rao, the study’s lead scientist, added, “Our findings highlight the necessity of personalized medicine for Alzheimer’s care. The variability in THC metabolism due to CYP2C9 polymorphisms points to the importance of genetic profiling in treatment plans, paving the way for tailored therapeutic approaches and potentially better patient outcomes.”
IGC Pharma is actively conducting a phase 2 trial for IGC-AD1, a partial CB1 receptor agonist with anti-neuroinflammatory properties and an inflammasome inhibitor. IGC-AD1 targets agitation symptoms in dementia due to Alzheimer’s, leveraging THC as a primary active component. This innovative formulation represents a pioneering approach in Alzheimer’s therapy.
IGC Pharma, Inc. says it is at the forefront of Alzheimer’s research, committed to transforming treatment paradigms for this debilitating disease. With a robust pipeline of five promising drug candidates, including IGC-AD1 and LMP targeting neuroinflammation and hallmark Alzheimer’s symptoms, IGC Pharma is dedicated to delivering breakthrough therapies. Their advanced research also involves leveraging artificial intelligence (AI) to optimize clinical trials and enhance early detection of Alzheimer’s.
